Cagrilintide vs Semaglutide: Two Hormone Systems, One Combination

Semaglutide is an analogue of GLP-1, an incretin released from the gut in response to a meal. Its documented actions run through the GLP-1 receptor: glucose-dependent insulin secretion, slowed gastric emptying, and central effects on satiety.[1] The molecule is engineered for a long half-life with DPP-4-resistant substitutions and albumin-binding acylation.[4]

Cagrilintide is a long-acting analogue of amylin, a 37-residue hormone co-secreted with insulin by pancreatic beta cells. Amylin signals through a receptor family built from the calcitonin receptor in complex with receptor activity-modifying proteins, and its documented role is satiation signalling and the regulation of gastric emptying.[5]

That is the substance of the comparison. These are not two GLP-1 analogues with different half-lives. They are agonists at unrelated receptor families that happen to converge on overlapping physiological endpoints, which is precisely the property that makes combining them interesting rather than redundant.

Amino Acid Sequence

Amino Acid Sequence

The combination was tested precisely on the thesis that two complementary satiety systems do more than one. A phase 1b study established that the two could be co-administered,[3] a phase 2 programme followed,[2] and the combination has since been reported among the strongest results published in this class.

For research purposes the design principle is the transferable part: non-overlapping receptor systems with converging outputs. It is the same reasoning that puts a GHRH analogue alongside a growth-hormone secretagogue rather than choosing between them, and the same reasoning behind most defensible peptide combinations. The logic is set out generally in peptide blends explained.

Neither cagrilintide on its own nor the combination is approved anywhere. Semaglutide is approved in its pharmaceutical forms, which are separate regulated medicines and not what is supplied here.

• ·Hormone system. Semaglutide: GLP-1, a gut incretin. Cagrilintide: amylin, a pancreatic hormone co-secreted with insulin.
• ·Receptor. Semaglutide: the GLP-1 receptor. Cagrilintide: amylin receptors, formed from the calcitonin receptor in complex with receptor activity-modifying proteins.
• ·Evidence stage. Semaglutide: completed phase 3 programmes and cardiovascular outcome data. Cagrilintide: phase 1 and phase 2 data alone and in combination, no approval.
• ·Engineering. Both are lipidated for a long half-life, which is why both are relatively demanding syntheses and neither is a cheap compound to make properly.
• ·Where each is useful in a panel. Semaglutide as the documented incretin reference. Cagrilintide as the amylin-pathway comparator, and as the second half of any combination question.

Cagrilintide is a lipidated synthesis, which means extra steps, lower yields and a genuinely high cost floor. A compound that is expensive to make correctly and hard to distinguish by eye is the classic setup for substitution and for short fills, and the same market-surveillance literature that documented quality failures in online semaglutide products[6] is a fair warning for the neighbouring compound.

The standard is the same for both: mass-spectrometric identity against the theoretical mass, HPLC purity, and measured content against the labelled amount, published per lot before sale and verifiable on the testing laboratory's own database. A certificate showing purity alone answers one of the three questions and leaves the two that cost money unanswered.

Published Certificate

Select strength

5mg10mg

Batch

CAG-CA-26A-01

Purity (HPLC)

Not reported

Measured content

Not reported

Laboratory

Not reported

Verify on the lab’s own databaseAll published certificates

Published Certificate

Batch

SEMA-CA-26F-10

Purity (HPLC)

99.504%

Measured content

11.27 mglabelled 10 mg

Laboratory

Janoshik

Verify on the lab’s own databaseAll published certificates

There is no sensible ranking here. A question about incretin pharmacology needs semaglutide. A question about amylin-pathway signalling needs cagrilintide. A question about whether two satiety systems are additive needs both, run as separate single-compound reagents so the ratio stays a variable the researcher controls.

Both are stocked as separate compounds with their own lot certificates.

Eppix Labs catalogue

Buy Cagrilintide Canada | Amylin Analog

5mg · 10mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $90.00 CADOut of stock

Available at Eppix Labs

Buy Semaglutide Canada | GLP-1

10mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $70.00 CADIn stock